Cyclin-dependent kinase inhibitors closer to market launch?

Bibliography

• Ward RA, Goldberg F. Drug discovery and non-human kinomes. In: Ward RA, Goldberg F, editors. Kinase drug discovery. RSC Publishing, UK; 2012. p. 262-85
   Google Scholar
• Fedorov O, Muller S, Knapp S. The (un)targeted cancer kinome. Nat Chem Biol 2010;6:166-9
   PubMed Web of Science ®Google Scholar
• Zhang HH, Zhang XQ, Wang WY, Increased synaptophysin is involved in inflammation-induced heat hyperalgesia mediated by cyclin-dependent kinase 5 in rats. PLoS One 2012;7:e46666
   Google Scholar
• Frontini M, Kukalev A, Leo E, The CDK subunit CKS2 counteracts CKS1 to control cyclin A/CDK2 activity in maintaining replicative fidelity and neurodevelopment. Dev Cell 2012;23:356-70
   PubMedGoogle Scholar
• Cicenas J, Valius M. The CDK inhibitors in cancer research and therapy. J Cancer Res Clin Oncol 2011;137:1409-18
   PubMed Web of Science ®Google Scholar
• Chang KH, de Pablo Y, Lee HP, Cdk5 is a major regulator of p38 cascade: relevance to neurotoxicity in Alzheimer's disease. J Neurochem 2010;113:1221-9
   PubMedGoogle Scholar
• Koedel U, Frankenberg T, Kirschnek S, Apoptosis is essential for neutrophil functional shutdown and determines tissue damage in experimental pneumococcal meningitis. PLoS Pathog 2009;5:e1000461
   PubMed Web of Science ®Google Scholar
• Menn B, Bach S, Blevins TL, Delayed treatment with systemic (S)-roscovitine provides neuroprotection and inhibits in vivo CDK5 activity increase in animal stroke models. PLoS One 2010;5:e12117
   PubMed Web of Science ®Google Scholar
• Obligado SH, Ibraghimov-Beskrovnaya O, Zuk A, CDK/GSK-3 inhibitors as therapeutic agents for parenchymal renal diseases. Kidney Int 2008;73:684-90
   PubMed Web of Science ®Google Scholar
• Krystof V, Chamrad I, Jorda R, Pharmacological targeting of CDK9 in cardiac hypertrophy. Med Res Rev 2010;30:646-66
   PubMed Web of Science ®Google Scholar
• Kashanchi F, Kehn-Hall K. Cyclin dependent kinases as attractive targets to prevent transcription from viral genomes. Curr Pharm Des 2009;15:2520-32
   PubMedGoogle Scholar
• Malumbres M, Barbacid M. Cell cycle, CDKs and cancer: a changing paradigm. Nat Rev Cancer 2009;9:153-66
   PubMed Web of Science ®Google Scholar
• Slovackova J, Smarda J, Smardova J. Roscovitine-induced apoptosis of H1299 cells depends on functional status of p53. Neoplasma 2012;59:606-12
   PubMedGoogle Scholar
• Ramaswamy B, Phelps MA, Baiocchi R, A dose-finding, pharmacokinetic and pharmacodynamic study of a novel schedule of flavopiridol in patients with advanced solid tumors. Invest New Drugs 2012;30:629-38
   PubMed Web of Science ®Google Scholar
• Le Tourneau C, Faivre S, Laurence V, Phase I evaluation of seliciclib (R-roscovitine), a novel oral cyclin-dependent kinase inhibitor, in patients with advanced malignancies. Eur J Cancer 2010;46:3243-50
   PubMed Web of Science ®Google Scholar
• Tong WG, Chen R, Plunkett W, Phase I and pharmacologic study of SNS-032, a potent and selective Cdk2, 7, and 9 inhibitor, in patients with advanced chronic lymphocytic leukemia and multiple myeloma. J Clin Oncol 2010;28:3015-22
   PubMed Web of Science ®Google Scholar
• Leonard JP, LaCasce AS, Smith MR, Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma. Blood 2012;119:4597-607
   PubMed Web of Science ®Google Scholar
• Mahadevan D, Plummer R, Squires MS, A phase I pharmacokinetic and pharmacodynamic study of AT7519, a cyclin-dependent kinase inhibitor in patients with refractory solid tumors. Ann Oncol 2011;22:2137-43
   PubMed Web of Science ®Google Scholar
• Siemeister G, Lucking U, Wengner AM, BAY 1000394, a novel cyclin-dependent kinase inhibitor, with potent antitumor activity in mono- and in combination treatment upon oral application. Mol Cancer Ther 2012;11:2265-73
   PubMed Web of Science ®Google Scholar
• Hirte HW, Raghunadharao D, Baetz T, A phase 1 study of the selective cyclin dependent kinase inhibitor P276-00 in patients with advanced refractory neoplasms. J Clin Oncol ASCO Annual Meeting Proceedings Part I 2007;18S:14117
   Google Scholar
• de Bruijn P, Moghaddam-Helmantel IM, de Jonge MJ, Validated bioanalytical method for the quantification of RGB-286638, a novel multi-targeted protein kinase inhibitor, in human plasma and urine by liquid chromatography/tandem triple-quadrupole mass spectrometry. J Pharm Biomed Anal 2009;50:977-82
   PubMed Web of Science ®Google Scholar
• Stone A, Sutherland RL, Musgrove EA. Inhibitors of cell cycle kinases: recent advances and future prospects as cancer therapeutics. Crit Rev Oncog 2012;17:175-98
   PubMedGoogle Scholar
• Pevarello P, Villa P. Cyclin-dependent kinase inhibitors: a survey of the recent patent literature. Expert Opin Ther Pat 2005;15:675-703
   Web of Science ®Google Scholar
• Galons H, Oumata N, Meijer L. Cyclin-dependent kinase inhibitors: a survey of recent patent literature. Expert Opin Ther Pat 2010;20:377-404
   PubMed Web of Science ®Google Scholar
• Aggennix. Aminoindeno[1,2-c]pyrazol-4-ones as inhibitors of cyclin-dependent kinases useful for the treatment of alopecia, viral infections and hyperproliferative disorders A pharmaceutical composition and uses related thereto. SG173222; 2011
   Google Scholar
• Amgen. Fused tricyclic dual inhibitors of CDK 4/6 and FLT3. WO129344; 2012
   Google Scholar
• Anygen. Indirubin-3'-oxime derivatives as potent cyclin dependent kinase inhibitors. WO096676; 2011
   Google Scholar
• Liao XM, Leung KN. Indirubin-3'-oxime induces mitochondrial dysfunction and triggers growth inhibition and cell cycle arrest in human neuroblastoma cells. Oncol Rep 2013;29:371-9
   PubMedGoogle Scholar
• Vougogiannopoulou K, Ferandin Y, Bettayeb K, Soluble 3',6-substituted indirubins with enhanced selectivity toward glycogen synthase kinase-3 alter circadian period. J Med Chem 2008;51:6421-31
   PubMed Web of Science ®Google Scholar
• Astex. Combinations of pyrazole derivatives for the inhibition of CDKs and GSKs. US021420; 2010
   Google Scholar
• Astex. Pharmaceutical compounds. US0004243; 2010
   Google Scholar
• Astex. Benzimidazole compounds that modulate the activity of CDK, GSK and aurora kinases. EP2395000; 2011
   Google Scholar
• Howard S, Berdini V, Boulstridge JA. Fragment-based discovery of the pyrazol-4-yl urea (AT9283), a multitargeted kinase inhibitor with potent aurora kinase activity. J Med Chem 2009;52:379-88
   PubMed Web of Science ®Google Scholar
• Bayer. Sulfone-substituted anilinopyrimidine derivatives as CDK inhibitors the production thereof, and use as a medicine. US0251222; 2011
   Google Scholar
• Bayer. Schering Pharma. Sulfoxide substituted aniline pyrimidine derivatives as CDK inhibitors, their manufacture and use as medicine. EP2179993; 2010
   Google Scholar
• Bayer. Sulfoximine-substituted anilinopyrimidine derivatives as CDK inhibitors the production thereof, and use as medicine. US0294838; 2011
   Google Scholar
• Cyclacel. Combinaison of a purine-based CDK inhibitor with a tyrosine kinase inhibitor and use thereof in the treatment of proliferative disorders. US0143350; 2010
   Google Scholar
• Wilson SC, Atrasha B, Barlow C. Design, synthesis and biological evaluation of 6-pyridylmethylaminopurines as CDK inhibitors. Bioorg Med Chem Lett 2011;19:6949-65
   Google Scholar
• Cyclacel. Crystalline forms of a purine derivative. WO089401; 2011
   Google Scholar
• Gilead. Imidazolyl pyrimidine inhibitor compounds. WO009139; 2010
   Google Scholar
• Gilead. Oxindolyl inhibitor compounds. WO009166; 2010
   Google Scholar
• Gilead. Fused heterocyclic inhibitor compounds. WO009155; 2010
   Google Scholar
• Gilead. Imidazole derivatives and their use as modulators of cyclin dependent kinase. WO125402; 2010
   Google Scholar
• Hoffman la roche. Benzotriazole kinase modulators. WO028860; 2008
   Google Scholar
• Nerviano. CDK inhibitor in the treatment of mesothelioma. WO058006; 2010
   Google Scholar
• Nerviano. Use of a CDK inhibitor for the treatment of glioma. WO012733; 2010
   Google Scholar
• Nerviano. Use of a CDK inhibitor for the treatment of thymona. WO106028; 2010
   Google Scholar
• Nissan. Alpha-amino acid derivatives and medicaments containing the same as an active ingredient. US7,879,887; 2011
   Google Scholar
• Novartis. Organic compounds and their use. WO079933; 2008
   Google Scholar
• Novartis. Pyrazinylpyridines useful for treatment of proliferative diseases. WO0026904; 2011
   Google Scholar
• Novartis and Astex. Pyrrolopyrimidine compounds as CDK inhibitors. WO020675; 2010
   Google Scholar
• Novartis and Astex. Pyrrolopyrimidine compounds as CDK inhibitors of CDK4/6. WO101409; 2011
   Google Scholar
• Piramal. A synergistic pharmaceutical combination for the treatment of pancreatic cancer. WO123889; 2012
   Google Scholar
• Piramal. Pyrrolidine-substituted flavones as radio-sensitizers for use in the treatment cancer. CA2761182; 2010
   Google Scholar
• Schering. New pyrazolopyrimidines as cyclin-dependent kinase inhibitor. JP2010180235; 2010
   Google Scholar
• CNRS. Perharidines as CDK inhibitors. US020065; 2010
   Google Scholar
• CNRS. Method if treatment of polycystic disease and chronic lymphocytic leukemia. WO103473; 2010
   Google Scholar
• Bettayeb K, Oumata N, Echalier A. CR8, a potent and selective, roscovitine-derived inhibitor of cyclin-dependent kinases. Oncogene 2008;27:5797-807
   PubMed Web of Science ®Google Scholar
• Bukanov NO, Moreno SE, Natoli TA. CDK inhibitors R-roscovitine and S-CR8 effectively block renal and hepatic cystogenesis in an orthologous model of ADPKD. Cell Cycle 2012;11:4040-6
   PubMed Web of Science ®Google Scholar
• CNRS. Pyrazolo[1,5-a]triazine derivatives, preparation thereof, and therapeutic use thereof. US184557; 2012
   Google Scholar
• Dalian University. Cyclin dependent kinases inhibitor scutellaria flavonoid organic amine derivatives, preparation method and application thereof. CN101591322; 2009
   Google Scholar
• Georgetown University. Fluorescent cdk inhibitors for treatment of cancer. WO019967; 2010
   Google Scholar
• Ringer L, Sirajuddin P, Yenugonda VM. VMY-1-103, a dansylated analog of purvalanol B, induces caspase-3-dependent apoptosis in LNCaP prostate cancer cells. Bioorg Med Chem 2011;19:2714-25
   PubMedGoogle Scholar
• Hong Kong University. CDK5 Inhibitors and therapeutic uses thereof. US270821; 2012
   Google Scholar
• Nottingham University. Compounds for treating proliferative disorders. WO161446; 2011
   Google Scholar
• Univerzita Palackeho. Substituted 6-(2-aminobenzylamino)purine derivatives, their use as medicaments and preparations containing these compounds. WO085924; 2010
   Google Scholar
• Krystof V, McNae IW, Walkinshaw MD, Antiproliferative activity of olomoucine II, a novel 2,6,9-trisubstituted purine cyclin-dependent kinase inhibitor. Cell Mol Life Sci 2005;62:1763-71
   PubMed Web of Science ®Google Scholar
• Tokyo University. Inhibition of replication of hepatitis C virus by CDK inhibitor. WO 013466; 2010
   Google Scholar
• Massard C, Soria JC, Anthoney DA. A first in man, phase I dose-escalation study of PHA-793887, an inhibitor of multiple cyclin-dependent kinases (CDK2, 1 and 4) reveals unexpected hepatotoxicity in patients with solid tumors. Cell Cycle 2011;10:963-70
   PubMed Web of Science ®Google Scholar
• Betzi S, Alam R, Martin M. Discovery of a potential allosteric ligand binding site in CDK2. ACS Chem Biol 2011;6:492-501
   PubMed Web of Science ®Google Scholar
• Fischmann TO, Hruza A, Duca JS. Structure-guided discovery of cyclin-dependent kinase inhibitors. Biopolymers 2008;89:372-9
   PubMed Web of Science ®Google Scholar
• Bettayeb K, Oumata N, Echalier A, C&R8. a potent and selective, roscovitine-derived inhibitor of cyclin-dependent kinases. Oncogene 2008;27:5797-807
   PubMed Web of Science ®Google Scholar
• Bettayeb K, Baunbæk D, Delehouze C. CDK inhibitors roscovitine and CR8 trigger Mcl-1 down-regulation and apoptotic cell death in neuroblastoma cells. Genes Cancer 2010;1:369-80
   Google Scholar
• Squires S, Cooke Lock V. AT7519 a cyclin-dependent kinase inhibitor exerts its effects by transcriptional inhibition in leukemia cell lines and patient samples. Mol Cancer Ther 2010;9:920-8
   PubMed Web of Science ®Google Scholar
• Parry D, Timothy Guzi T, Shanahan F. Dinaciclib (SCH 727965), a novel and potent cyclin-dependent kinase inhibitor. Mol Cancer Ther 2010;9:2344
   PubMed Web of Science ®Google Scholar
• Malumbres M, Pevarello P, Barbacid M. CDK inhibitors in cancer therapy: what is next? Trends Pharmacol Sci 2007;29:16-21
   PubMedGoogle Scholar
• Guha M. Cyclin dependent kinase inhibitors move into Phase III. Nature Rev Drug Discovery 2012;11:892-4
   PubMed Web of Science ®Google Scholar
• Nair BJ, Vallabhanen S, Tekmal RR. Roscovitine confers tumor suppressive effect on therapy-resistant breast tumor cells. Breast Cancer Res 2011;13:R80
   PubMed Web of Science ®Google Scholar
• Booher R, Hirsch H, Peter Strack P. Mcl-1 dependency is a predictive biomarker for apoptotic induction by short-term dinaciclib (SCH 727965) treatment. Cancer Res 2012;72(Suppl 8): abstract 3063
   Google Scholar
• Horiuchi D, Kusdra L, Huskey NE. MYC pathway activation in triple-negative breast cancer is synthetic lethal with CDK inhibition. J Exp Med 2012;209:679-96
   PubMed Web of Science ®Google Scholar
• Nanos-Webb A, Jabbour NA. Targeting low molecular weight cyclin E (LMW-E) in breast cancer. Breast Cancer Res Treat 2012;132:575-88
   PubMed Web of Science ®Google Scholar
• Feldmann G, Mishra A, Bisht S. Cyclin-dependent kinase inhibitor Dinaciclib (SCH727965) inhibits pancreatic cancer growth and progression in murine xenograft models. Cancer Biol Ther 2011;12:598-609
   PubMed Web of Science ®Google Scholar
• Subramaniam D, Periyasamy G, Ponnurangam S. CDK-4 inhibitor P276 sensitizes pancreatic cancer cells to gemcitabine-induced apoptosis. Mol Cancer Ther 2012;11:1598-608
   PubMedGoogle Scholar
• Winter GE, Rix U, Carlson SM. Systems-pharmacology dissection of a drug synergy in imatinib-resistant CML. Nature Chem Biol 2012;8:905-12
   PubMed Web of Science ®Google Scholar
• http://www.cyclacel.com/research_programs_oncology_cyc202.shtml
   Google Scholar
• Martin KL, Hill GA, Klein RR. Prevention of radiation-induced salivary gland dysfunction utilizing a CDK inhibitor in a mouse model. PLoS ONE 2012;7:e51363
   Google Scholar
• Lange CA, Yee D. K4/6 inhibitor PD-0332991, in combinaison with the aromatase inhibitor LetrozoleKilling the second messenger: targeting loss of cell cycle control in endocrine-resistant breast cancer. Endocr Relat Cancer 2011;18:19-24
   PubMed Web of Science ®Google Scholar
• Flynn JM, Jones JA, Andritsos L. Phase I study of the CDK inhibitor dinaciclib (SCH 727965) in patients (pts) with relapsed/refractory CLL. J Clin Oncol 2011;29(Suppl):abstract 6623
   Google Scholar